{"doi":"10.1200/po.23.00407","title":"Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2","abstract":"PURPOSE: Subprotocol K2 (EAY131-K2) of the NCI-MATCH platform trial was an open-label, single-arm, phase II study designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients with tumors harboring FGFR1-4 mutations or fusions. METHODS: Central confirmation of tumor FGFR1-4 mutations or fusions was required for outcome analysis. Patients with urothelial carcinoma were excluded. Enrolled subjects received oral erdafitinib at a starting dose of 8 mg daily continuously until intolerable toxicity or disease progression. The primary end point was objective response rate (ORR) with key secondary end points of safety, progression-free survival (PFS), and overall survival (OS). RESULTS: = .034 against the null rate of 5%). An additional seven patients experienced stable disease as best-confirmed response. Four patients had a prolonged PFS including two with recurrent WHO grade IV, IDH1-/2-wildtype glioblastoma. The median PFS and OS were 3.6 months and 11.0 months, respectively. Erdafitinib was manageable with no new safety signals. CONCLUSION: This study met its primary end point in patients with several pretreated solid tumor types harboring FGFR1-3 mutations or fusions. These findings support advancement of erdafitinib for patients with fibroblast growth factor receptor-altered tumors outside of currently approved indications in a potentially tumor-agnostic manner.","journal":"JCO Precision Oncology","year":2024,"id":438184,"datarank":0.47600012771758243,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.11631583679782674,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.11631583679782674,"corpus_percentile":59.94430262241819,"corpus_rank":5179,"citation_count":10,"citer_count":10,"citers_with_citation_signal":8,"citers_with_endowment":8,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.5041,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":719650,"name":"Alain C. Mita","orcid":"0000-0002-5387-0160","position":1,"is_corresponding":false},{"id":345564,"name":"Zihan Wei","orcid":"0000-0001-9234-3497","position":2,"is_corresponding":false},{"id":251018,"name":"Heather H. Cheng","orcid":"0000-0002-1365-0702","position":3,"is_corresponding":false},{"id":241720,"name":"Edith P. Mitchell","orcid":"0000-0002-6788-7086","position":4,"is_corresponding":false},{"id":265353,"name":"John J. Wright","orcid":null,"position":5,"is_corresponding":false},{"id":256297,"name":"S. Percy Ivy","orcid":"0000-0001-7747-072X","position":6,"is_corresponding":false},{"id":32007,"name":"Victoria Wang","orcid":null,"position":7,"is_corresponding":false},{"id":241715,"name":"Robert J. Gray","orcid":"0000-0002-5724-4917","position":8,"is_corresponding":false},{"id":34528,"name":"Lisa M. McShane","orcid":"0000-0001-8195-3206","position":9,"is_corresponding":false},{"id":72418,"name":"Larry Rubinstein","orcid":"0000-0002-9720-9737","position":10,"is_corresponding":false},{"id":241718,"name":"David R. Patton","orcid":"0000-0003-3855-0166","position":11,"is_corresponding":false},{"id":241719,"name":"P. Mickey Williams","orcid":"0000-0002-3309-5988","position":12,"is_corresponding":false},{"id":29240,"name":"Stanley R. Hamilton","orcid":"0000-0002-8331-1052","position":13,"is_corresponding":false},{"id":241728,"name":"James V. Tricoli","orcid":"0000-0003-3975-8516","position":14,"is_corresponding":false},{"id":241734,"name":"Barbara A. Conley","orcid":"0000-0002-1445-1684","position":15,"is_corresponding":false},{"id":241731,"name":"Carlos L. Arteaga","orcid":"0000-0003-0870-9586","position":16,"is_corresponding":false},{"id":241722,"name":"Lyndsay N. Harris","orcid":"0000-0002-9774-6719","position":17,"is_corresponding":false},{"id":74906,"name":"Peter J. O’Dwyer","orcid":"0000-0002-9302-4073","position":18,"is_corresponding":false},{"id":1073535,"name":"Alice P. Chen","orcid":"0000-0002-2919-4326","position":19,"is_corresponding":false},{"id":410,"name":"Keith T. Flaherty","orcid":"0000-0002-3402-0478","position":20,"is_corresponding":false},{"id":415654,"name":"Jun Gong","orcid":"0000-0001-8713-1406","position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-19T02:00:38.888629Z","pmid":"38603650","pmcid":"PMC11623915","fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}